Cargando…

The Prognostic Value of PARP Expression in High-Grade Epithelial Ovarian Cancer

In an attempt to clarify the prognostic relevance of poly (ADP-ribose) polymerase (PARP) expression, we analysed the clinical data of 86 high-grade epithelial ovarian cancer (EOC) cases in which PARP immunohistochemistry results were available. Immunostaining to highlight PARP protein expression was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molnár, Szabolcs, Beke, Lívia, Méhes, Gábor, Póka, Róbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471102/ https://www.ncbi.nlm.nih.gov/pubmed/32594311 http://dx.doi.org/10.1007/s12253-020-00856-6

Ejemplares similares

The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients
por: Molnár, Szabolcs, et al.
Publicado: (2021)

Grade Group accuracy is improved by extensive prostate biopsy sampling, but unrelated to prostatectomy specimen sampling or use of immunohistochemistry
por: Korpás, Kristóf Levente, et al.
Publicado: (2023)

High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma
por: Jank, Paul, et al.
Publicado: (2023)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Carbonic Anhydrase IX Expression and Treatment Response Measured in Rectal Adenocarcinoma Following Neoadjuvant Chemo-Radiotherapy
por: Bádon, Emese Sarolta, et al.
Publicado: (2023)

High Genetic Diversity and No Evidence of Clonal Relation in Synchronous Thyroid Carcinomas Associated with Hashimoto’s Thyroiditis: A Next-Generation Sequencing Analysis
por: Molnár, Csaba, et al.
Publicado: (2020)

Anastomosing Haemangioma: Report of Three Cases With Molecular and Immunohistochemical Studies and Comparison With Well-Differentiated Angiosarcoma
por: Chang Chien, Yi-Che, et al.
Publicado: (2022)

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
por: Raspaglio, Giuseppina, et al.
Publicado: (2023)

Expression and prognostic value of CLIC1 in epithelial ovarian cancer
por: Yu, Wentao, et al.
Publicado: (2018)

The Prognostic Values of PARP-1 Expression in Uveal Melanoma
por: Gajdzis, Malgorzata, et al.
Publicado: (2021)

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines
por: Fleury, Hubert, et al.
Publicado: (2016)

Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
por: Zhang, Lu, et al.
Publicado: (2021)

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
por: Gien, Lilian T., et al.
Publicado: (2010)

PARP-1 may be involved in angiogenesis in epithelial ovarian cancer
por: Wei, Wei, et al.
Publicado: (2016)

Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer
por: Sahin, Irem Durmaz, et al.
Publicado: (2019)

The prognostic value of morphometry in advanced epithelial ovarian cancers.
por: Katsoulis, M., et al.
Publicado: (1995)

Prognostic gene expression signature for high-grade serous ovarian cancer
por: Millstein, J., et al.
Publicado: (2020)

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
por: Huang, Xuan-zhang, et al.
Publicado: (2020)

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
por: Dickson, Kristie-Ann, et al.
Publicado: (2021)

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells
por: Jia, Yaxun, et al.
Publicado: (2022)

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
por: Ray-Coquard, Isabelle, et al.
Publicado: (2020)

Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
por: Revythis, Antonios, et al.
Publicado: (2022)

BRCA mutation in high grade epithelial ovarian cancers
por: Manchana, Tarinee, et al.
Publicado: (2019)

The prognostic value of ITGA and ITGB superfamily members in patients with high grade serous ovarian cancer
por: Zhu, Tingting, et al.
Publicado: (2020)

The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer
por: de Graeff, P, et al.
Publicado: (2008)

Prognostic value of preoperative hyponatremia in patients with epithelial ovarian cancer
por: Guo, Jing-Yi, et al.
Publicado: (2019)

Carbonic Anhydrase Inhibitor Acetazolamide Enhances CHOP Treatment Response and Stimulates Effector T-Cell Infiltration in A20/BalbC Murine B-Cell Lymphoma
por: Méhes, Gábor, et al.
Publicado: (2020)

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system
por: Bound, Nirashaa T., et al.
Publicado: (2022)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
por: Jiang, Yifan, et al.
Publicado: (2020)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma
por: Marchenko, Sofya, et al.
Publicado: (2022)

Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP
por: Yokoyama, Takuhei, et al.
Publicado: (2017)

High Expression of PARP1 in Tumor and Stroma Cells Predicts Different Prognosis and Platinum Resistance in Patients With Advanced Epithelial Ovarian Cancer
por: Zuo, Wei-Wei, et al.
Publicado: (2022)

Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer
por: Zuo, Wei-Wei, et al.
Publicado: (2023)

Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
por: Kanakkanthara, Arun, et al.
Publicado: (2022)

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
por: Lu, Xue, et al.
Publicado: (2022)

PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective
por: Loizzi, Vera, et al.
Publicado: (2020)

Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer
por: Gong, Weiwei, et al.
Publicado: (2020)

Quantitative Analysis of Carbonic Anhydrase IX Uncovers Hypoxia-Related Functional Differences in Classical Hodgkin Lymphoma Subtypes
por: Matolay, Orsolya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6lnkqjklhtvo6cts04ap7kkukc